CeriBell (NASDAQ:CBLL) Stock Price Down 7.8% – Time to Sell?

CeriBell, Inc. (NASDAQ:CBLL)’s stock price fell 7.8% on Thursday . The stock traded as low as $16.60 and last traded at $16.51. 242,264 shares traded hands during trading, a decline of 24% from the average session volume of 319,536 shares. The stock had previously closed at $17.91.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on CBLL. BTIG Research restated a “buy” rating and set a $30.00 price target on shares of CeriBell in a report on Wednesday, January 28th. Weiss Ratings cut CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. Finally, Canaccord Genuity Group reduced their price target on CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, CeriBell presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.20.

CeriBell Stock Performance

The company has a fifty day moving average price of $19.11 and a two-hundred day moving average price of $18.88. The company has a market capitalization of $618.42 million, a P/E ratio of -10.00 and a beta of 0.99. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.44 and a quick ratio of 9.35.

CeriBell (NASDAQ:CBLL) last announced its earnings results on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.13). CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. The company had revenue of $26.49 million during the quarter, compared to the consensus estimate of $26.09 million. Equities analysts forecast that CeriBell, Inc. will post -1.68 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Xingjuan Chao sold 39,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $20.10, for a total value of $783,900.00. Following the sale, the chief executive officer directly owned 836,347 shares in the company, valued at $16,810,574.70. This represents a 4.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP David Foehr sold 4,560 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $17.80, for a total value of $81,168.00. Following the completion of the sale, the vice president owned 17,550 shares in the company, valued at $312,390. The trade was a 20.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 175,119 shares of company stock valued at $3,310,772. Insiders own 20.10% of the company’s stock.

Hedge Funds Weigh In On CeriBell

Institutional investors have recently added to or reduced their stakes in the business. Strs Ohio acquired a new position in CeriBell in the first quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd lifted its stake in CeriBell by 3,971.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after buying an additional 1,231 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in CeriBell in the third quarter valued at approximately $33,000. CWM LLC lifted its stake in CeriBell by 1,178.5% in the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after buying an additional 1,697 shares during the period. Finally, Tower Research Capital LLC TRC lifted its stake in CeriBell by 353.8% in the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after buying an additional 1,801 shares during the period.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.